Finanzen von Entrada Therapeutics Inc (TRDA)TRDAEntrada Therapeutics Inc

Evaluating the bottom line, Entrada Therapeutics, Inc. maintains a gross margin of 100.00%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -5007.02%, while the net margin is -4762.03%. These profitability ratios, combined with a Return on Equity (ROE) of -54.09%, provide a clear picture of how effectively TRDA converts its operational activities into shareholder value.

In the context of the broader market, TRDA competes directly with industry leaders such as SION and IVVD. With a market capitalization of $197.04M, it holds a leading position in the sector. When comparing efficiency, TRDA's gross margin of 100.00% stands against SION's N/A and IVVD's 91.09%. Such benchmarking helps identify whether Entrada Therapeutics, Inc. is trading at a premium or discount relative to its financial performance.

Entrada Therapeutics has shown a significant decline in revenue, with Q2 2026 collaboration revenue at only $0.89 million, down from $1.95 million in Q2 2025. The company has also reported substantial net losses, including a loss of $42.76 million in Q2 2026, which is an improvement from $43.1 million in Q2 2025, but still highlights ongoing financial challenges.